Companies Dominating the Hidradenitis Suppurativa Market
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- AstraZeneca
- Merck & Co., Inc.
- Bayer AG
- AbbVie Inc.
- Abbott
Browse Key Market Insights with Data Illustration:
In the News
March 26, 2024: F. Hoffmann-La Roche Ltd., declared the U.S. Food and Drug Administration (FDA) acceptance of the cobas® Malaria test for utilization on the cobas® 6800/8800 Systems. This accepted test can help healthcare professionals in limiting the possible risks of patient infection from imbued blood materials. The cobas Malaria test gives a highly sensitive and particular solution to assist confirm that polluted blood units are eliminated from the blood supply.
March 05, 2024: F. Hoffmann-La Roche Ltd. and Alnylam declared that the Phase II KARDIA-2 study [NCT05103332] of zilebesiran, an examinational RNAi therapeutic in growth for the therapy of hypertension (high blood pressure) - the foremost cause of cardiovascular disease globally - met its basic endpoint. People with mild to intermediate hypertension cured with zilebesiran added to standard-of-care hypertension medicines experienced a clinically and numerically substantial limitation in systolic blood pressure at month three.
